Korro Bio Inc. has nominated KRRO-121 as its next development candidate, for the treatment of patients with hyperammonemia, including patients with urea cycle disorders and hepatic encephalopathy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results